Breast Carcinoma Profile I in Alibag

The "Breast Carcinoma Profile I" test is performed on a breast lumpectomy specimen to assess certain important markers in breast cancer, including Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2/neu). The test involves immunohistochemistry (IHC) staining for ER, PR, and HER2/neu. If the HER2/neu test result is equivocal or borderline, it is reflexed to a fluorescence in situ hybridization (FISH) test for further evaluation. These markers play a crucial role in determining the molecular subtype of breast cancer and help guide treatment decisions. ER and PR status indicate whether the cancer is hormone receptor-positive or hormone receptor-negative, which is essential in choosing hormonal therapies. HER2/neu status is crucial for selecting targeted therapies that specifically inhibit the HER2 protein, which is overexpressed in some breast cancers. The results of this profile provide valuable information to oncologists in tailoring the most appropriate treatment plan for patients with breast carcinoma.